Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/14462
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Sanmartí Sala, Raimon | cat |
dc.contributor.author | Graell, Eduard | cat |
dc.contributor.author | Pérez, María L. | cat |
dc.contributor.author | Ercilla González, M. Guadalupe | cat |
dc.contributor.author | Viñas, Odette | cat |
dc.contributor.author | Gómez-Puerta, José Alfredo | cat |
dc.contributor.author | Gratacós, Jordi | cat |
dc.contributor.author | Balsa, Alejandro | cat |
dc.contributor.author | Gómara Elena, María José | cat |
dc.contributor.author | Larrosa, Marta | cat |
dc.contributor.author | Cañete Crespillo, Juan D. | cat |
dc.contributor.author | Haro Villar, Isabel | cat |
dc.date.accessioned | 2010-11-19T11:30:09Z | - |
dc.date.available | 2010-11-19T11:30:09Z | - |
dc.date.issued | 2009-09-02 | - |
dc.identifier.issn | 1478-6362 | - |
dc.identifier.uri | http://hdl.handle.net/2445/14462 | - |
dc.description.abstract | Introduction: Evidence suggests that citrullinated fibrin(ogen) may be a potential in vivo target of anticitrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis (RA). We compared the diagnostic yield of three enzyme-linked immunosorbent assay (ELISA) tests by using chimeric fibrin/filaggrin citrullinated synthetic peptides (CFFCP1, CFFCP2, CFFCP3) with a commercial CCP2-based test in RA and analyzed their prognostic values in early RA. Methods: Samples from 307 blood donors and patients with RA (322), psoriatic arthritis (133), systemic lupus erythematosus (119), and hepatitis C infection (84) were assayed by using CFFCP- and CCP2-based tests. Autoantibodies also were analyzed at baseline and during a 2-year follow-up in 98 early RA patients to determine their prognostic value. Results: With cutoffs giving 98% specificity for RA versus blood donors, the sensitivity was 72.1% for CFFCP1, 78.0% for CFFCP2, 71.4% for CFFCP3, and 73.9% for CCP2, with positive predictive values greater than 97% in all cases. CFFCP sensitivity in RA increased to 80.4% without losing specificity when positivity was considered as any positive anti-CFFCP status. Specificity of the three CFFCP tests versus other rheumatic populations was high (> 90%) and similar to those for the CCP2. In early RA, CFFCP1 best identified patients with a poor radiographic outcome. Radiographic progression was faster in the small subgroup of CCP2-negative and CFFCP1-positive patients than in those negative for both autoantibodies. CFFCP antibodies decreased after 1 year, but without any correlation with changes in disease activity. Conclusions: CFFCP-based assays are highly sensitive and specific for RA. Early RA patients with anti-CFFCP1 antibodies, including CCP2-negative patients, show greater radiographic progression. | eng |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | BioMed Central | eng |
dc.relation.isformatof | Reproducció del document publicat a http://dx.doi.org/10.1186/ar2802 | cat |
dc.relation.ispartof | Arthritis Research and Therapy, 2009, 11:R135 | eng |
dc.relation.uri | http://dx.doi.org/10.1186/ar2802 | - |
dc.rights | cc-by, (c) Sanmarti et al., 2009 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/2.0/ | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Artritis reumatoide | cat |
dc.subject.classification | Diagnòstic | cat |
dc.subject.other | Rheumatoid arthritis | eng |
dc.subject.other | Diagnosis | eng |
dc.title | Diagnostic and prognostic value of antibodies against chimeric fibrin/filaggrin citrullinated synthetic peptides in rheumatoid arthritis | eng |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 19725967 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
ar2802.pdf | 642.34 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License